Investing.com
Published Jul 14, 2025 07:54AM ET
Investing.com - H.C. Wainwright reiterated its Buy rating on Cognition Therapeutics (NASDAQ:CGTX) with a price target of $3.00 on Monday. Currently trading at $0.57, the micro-cap biotech company ($35.17M market cap) has analyst targets ranging from $2 to $4, according to InvestingPro data.
The firm's decision follows Cognition's end-of-Phase 2 meeting with the FDA on July 9, where the company discussed results from the Phase 2 SHINE study of zervimesine (CT1812) and plans for a Phase 3 program to support a New Drug Application in Alzheimer's disease. While the company maintains a healthy current ratio of 2.09, InvestingPro analysis shows rapid cash burn as a key concern.
Cognition is expected to receive formal, minuted feedback from the FDA next month that will outline the clinical path forward for zervimesine in Alzheimer's disease.
H.C. Wainwright noted that FDA feedback would represent a "meaningful clarity and a clear value inflection point" for Cognition, particularly if it required a 12-month evaluation period and specified that a single functional outcome measure would be sufficient as a primary endpoint.
The research firm maintains its 12-month price target of $3.00 in anticipation of FDA feedback that would facilitate a clear development path for zervimesine in Alzheimer's disease. For comprehensive analysis of biotech stocks like CGTX, including detailed financial health metrics and expert insights, explore InvestingPro 's extensive research tools.
In other recent news, Cognition Therapeutics has completed an end-of-Phase 2 meeting with the U.S. Food and Drug Administration regarding its Alzheimer's drug candidate, zervimesine. The meeting focused on reviewing results from the Phase 2 "SHINE" study and discussing plans for a Phase 3 program that would support a new drug application. The SHINE study, which enrolled 153 adults with mild-to-moderate Alzheimer's disease, met its primary endpoints of safety and tolerability. Cognition Therapeutics is also conducting the Phase 2 START Study, which has surpassed 50% enrollment and aims to evaluate zervimesine in patients with mild Alzheimer's disease. The study is supported by $81 million in grant funding from the National Institute of Aging. Analysts at H.C. Wainwright have reiterated their Buy rating and $3.00 price target on Cognition Therapeutics, reflecting confidence in the company's progress. Additionally, the company is advancing zervimesine for dementia with Lewy bodies and has submitted applications for Breakthrough Therapy Designation. An expanded access program for zervimesine in dementia with Lewy bodies is currently enrolling patients.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Written By: Investing.com
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.